No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Harbin Medisan Pharmaceutical (002900.SZ): All initial fundraising projects have been completed, and the surplus funds will permanently supplement working capital.
On February 18, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) announced that all funds raised from the initial public offering of stocks have reached the predetermined usable status, and the company will conclude all funded projects. In order to maximize the efficiency of fund use, the company intends to permanently supplement working capital with the remaining raised funds of 81.8757 million yuan (estimated amount, including financial investment income and bank deposit interest, with the actual amount based on the special account balance on the date of fund transfer) until January 31, 2025. After the transfer is completed, the company will terminate the special account for the raised funds.
Harbin Medisan Pharmaceutical (002900.SZ): Some formulation products have now achieved overseas sales.
On February 18, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) stated on the investor interaction platform that some of its formulation products have already achieved overseas sales, primarily in South America, while also developing other markets.
Harbin Medisan Pharmaceutical (002900.SZ): A total of 11.0817 million yuan in government subsidies received.
Gelonghui, December 30丨Harbin Medisan Pharmaceutical (002900.SZ) announced that from November 14, 2024, to December 29, 2024, the company and Peking Harbin Medisan Technology Co., Ltd. have received a total of 11.0817 million yuan in government subsidies.
Harbin Medisan Pharmaceutical (002900.SZ): Some pharmaceuticals are proposed to be awarded in centralized procurement.
On December 13, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) announced that the company and its wholly-owned subsidiary Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical") recently participated in the bidding for the 10th national centralized procurement organized by the National Organization of Pharmaceutical Concentrated Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). The company's pharmaceutical products, namely Esmolol Hydrochloride Injection, Theobromine Injection, and Potassium Chloride Injection, as well as Lanxi Pharmaceutical's product, Tandedrone Citrate Tablets, are expected to win the bid in this centralized procurement.
Harbin Medisan Pharmaceutical (002900.SZ): Received a total of 25.5098 million yuan in government subsidies.
Gelonghui, on November 18, announced that Harbin Medisan Pharmaceutical (002900.SZ) disclosed that its wholly-owned subsidiaries, Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical"), Guangzhou Harbin Medisan Biotechnology Co., Ltd. (hereinafter referred to as "Guangzhou Harbin Medisan"), Lanxi Harbin Medisan Medicine Co., Ltd. (hereinafter referred to as "Lanxi Medicine"), Harbin Sanlian Lide Biotechnology Co., Ltd. (hereinafter referred to as "Lide Biotechnology"), Lingbao Harbin Medisan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lingbao Harbin Medisan"), and Peking Harbin Medisan Technology Co., Ltd. (hereinafter referred to as "Peking Technology") will be active from February 4, 2024 to...
